News - Sanofi-Aventis

Filter

Current filters:

Sanofi-Aventis

Popular Filters

US FTC warns Sanofi, Watson and Synthon over Ambien patent deal, but won’t take action

11-05-2011

The Federal Trade Commission’s Bureau of Competition has notified Sanofi-Aventis US, a subsidiary…

AmbienGenericsLegalNorth AmericaPatentsPharmaceuticalSanofi-AventisSynthonWatson Pharmaceuticals

Sanofi-Aventis pulls out of diabetes accord with Metabolex; enters deal for malaria drugs; shortens name

09-05-2011

French drug major Sanofi-Aventis (Euronext: SAN) has pulled out of a drug development deal with California,…

DiabetesLicensingMetabolexPharmaceuticalSanofi-AventisTropical diseases

Sanofi-Aventis net profit in 1st-qrt 2011 slumps 29%, battered by generics and low flu sales

29-04-2011

French drug major Sanofi-Aventis (Euronext: SAN) posted first-quarter 2011 results yesterday, showing…

BiotechnologyFinancialGenzymePharmaceuticalSanofi-Aventis

Sanofi-Aventis and Regeneron’s Zaltrap improves OS in Ph III colon cancer study

28-04-2011

French drug major Sanofi-Aventis (Euronext: SAN) and USA-based partner Regeneron Pharmaceuticals (Nasdaq:…

afliberceptOncologyPharmaceuticalRegeneronResearchSanofi-AventisZaltrap

Sanofi-Aventis collaborates with Stanford University Bio-X on early-stage scientific research

19-04-2011

In yet another tie-up with academia, French drug major Sanofi-Aventis (Euronext: SAN) has entered into…

PharmaceuticalResearchSanofi-Aventis

Back to top